IntelliPharmaCeutics International Inc. [NASDAQ:IPCI]: Analyst Rating and Earnings
Equities traders frequently stay up to date regarding what leading market analysts think about a possible stock buy. As it relates to IntelliPharmaCeutics International Inc. [IPCI], the latest mean analyst recommendation that’s publicly available is from the fiscal three-month period ending in November. On average, stock market experts give IPCI an Outperform rating. Its stock price has been found in the range of 24.72 to 47.26. This is compared to its latest closing price of $0.29.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for IntelliPharmaCeutics International Inc. [IPCI] is sitting at 2.50. This is compared to 1 month ago, when its average rating was 2.00.
Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Fri 15 Feb (In 32 Days).
Fundamental Analysis of IntelliPharmaCeutics International Inc. [IPCI]
Now let’s turn to look at profitability: with a current Operating Margin for IntelliPharmaCeutics International Inc. [IPCI] sitting at -150.17 and its Gross Margin at +78.00.
This company’s Return on Total Capital is -384.21, and its Return on Invested Capital has reached -486.20%. Its Return on Equity is -1,178.91, and its Return on Assets is -115.25. These metrics show a mixed bag, which means that this investment’s attractiveness can be quickly increased or decreased in the short term, depending on future updates IPCI financial performance.
Turning to investigate this organization’s capital structure, IntelliPharmaCeutics International Inc. [IPCI] has generated a Total Debt to Total Equity ratio of 333.99. Similarly, its Total Debt to Total Capital is 76.96, while its Total Debt to Total Assets stands at 17.45.
What about valuation? This company’s Enterprise Value to EBITDA is -0.17. The Enterprise Value to Sales for this firm is now 0.55, and its Total Debt to Enterprise Value stands at 0.05. IntelliPharmaCeutics International Inc. [IPCI] has a Price to Book Ratio of 75.99.
Similarly, this company’s Receivables Turnover is 4.44 and its Total Asset Turnover is 0.72. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.74 and its Current Ratio is 0.77. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.
Let’s now turn our attention to trading performance: IntelliPharmaCeutics International Inc. [IPCI] has 8.36M shares outstanding, amounting to a total market cap of $2.80M. Its stock price has been found in the range of 0.20 to 10.50. At its current price, it has moved by -96.81% from its 52-week high, and it has moved 67.37% from its 52-week low.
This stock’s Beta value is currently 2.01, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 57.63. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is IntelliPharmaCeutics International Inc. [IPCI] a Reliable Buy?
Shares of IntelliPharmaCeutics International Inc. [IPCI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.